Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes
- Author(s)
- Meagher, NS; Gorringe, KL; Wakefield, MJ; Bolithon, A; Pang, CNI; Chiu, DS; Anglesio, MS; Mallitt, KA; Doherty, JA; Harris, HR; Schildkraut, JM; Berchuck, A; Cushing-Haugen, KL; Chezar, K; Chou, A; Tan, A; Alsop, J; Barlow, E; Beckmann, MW; Boros, J; Bowtell, DD; Brand, AH; Brenton, JD; Campbell, I; Cheasley, D; COHEN, J; Cybulski, C; Elishaev, E; Erber, R; Farrell, R; Fischer, A; Fu, Z; Gilks, B; Gill, AJ; Gourley, C; Grube, M; Harnett, P; Hartmann, A; Hettiaratchi, A; Høgdall, CK; Huzarski, T; Jakubowska, A; Jimenez-Linan, M; Kennedy, CJ; Kim, BG; Kim, JW; Kim, JH; Klett, K; Koziak, J; Lai, T; Laslavic, A; Lester, J; Leung, Y; Li, N; Liauw, W; Lim, BWX; Linder, A; Lubinski, J; Mahale, S; Mateoiu, C; McInerny, S; Menkiszak, J; Minoo, P; Mittelstadt, S; Morris, D; Orsulic, S; Park, SY; Pearce, CL; Pearson, JV; Pike, MC; Quinn, CM; Mohan, GR; Rao, J; Riggan, MJ; Ruebner, M; Salfinger, S; Scott, CL; Shah, M; Steed, H; Stewart, CJR; Subramanian, D; Sung, S; Tang, K; Timpson, P; Ward, RL; Wiedenhoefer, R; Thorne, H; Cohen, PA; Crowe, P; Fasching, PA; Gronwald, J; Hawkins, NJ; Høgdall, E; Huntsman, DG; James, PA; Karlan, BY; Kelemen, LE; Kommoss, S; Konecny, GE; Modugno, F; Park, SK; Staebler, A; Sundfeldt, K; Wu, AH; Talhouk, A; Pharoah, PDP; Anderson, L; DeFazio, A; Köbel, M; Friedlander, ML; Ramus, SJ;
- Journal Title
- Clinical Cancer Research
- Publication Type
- epub ahead of print
- Abstract
- PURPOSE: Advanced stage MOC have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathological and gene expression data were analysed to identify prognostic and diagnostic features. EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n=333), mucinous borderline ovarian tumors (MBOT, n=151), upper GI (n=65), and lower GI tumors (n=55). RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77 (1.04-7.41, p=0.042). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25 (95% CI 1.04-1.51, p=0.016)) and (1.21 (1.01-1.45, p=0.043)) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%). CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.
- Publisher
- AACR
- Research Division(s)
- Bioinformatics; Cancer Biology And Stem Cells
- PubMed ID
- 36222710
- Publisher's Version
- https://doi.org/10.1158/1078-0432.Ccr-22-1206
- Open Access at Publisher's Site
https://doi.org/10.1158/1078-0432.Ccr-22-1206- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-10-14 09:03:07
Last Modified: 2022-10-14 09:06:10